Dataset from A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin

The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple
combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes
after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of
this treatment will also be studied.